ABT Jun 2024 97.500 put
| Previous close | 0.3700 |
| Open | 0.3700 |
| Bid | 0.1300 |
| Ask | 1.1500 |
| Strike | 97.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.3700 - 0.3700 |
| Contract range | N/A |
| Volume | |
| Open interest | 826 |
ZacksDexCom (DXCM) Declines on Potential Competition for Stelo (revised)
DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.
- Yahoo Finance Video
NYSE resolves glitch that showed Berkshire Hathaway down 99%
A New York Stock Exchange glitch showed erroneous prices for several stocks, including Berkshire Hathaway class A shares (BRK-A), which were shown to be down 99.9%. The issue has since been resolved. In the video above, Yahoo Finance's Jared Blikre breaks down what happened on Wall Street today. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Stephanie Mikulich.
PR NewswireCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions.
